I'd like to thank all the members of the panel for what has been a very interesting discussion indeed.
Mr. Cassels, you talked about disease-mongering, and that's an interesting way of putting things. I've looked at the adverts, and there are some credible organizations on the advert you passed around, like the Canadian Diabetes Association and others. So I wonder if you could comment on the relation between what you call disease-mongering and the fact that very credible organizations have put their names on that advert.
To those who discussed the issue of the pharmaceuticals' ability to advertise, I can't get into the specifics of the cases, but there are two cases where the federal government is in court trying to keep the prohibition on advertising of pharmaceutical products. I'll throw that out to Mr. Cassels.
I would also like to hear Robyn's comments on post-market surveillance and the life-cycle approach, because that is really key to the legislation the minister has brought forward.